NuVasive, Inc. (NUVA) Tops Q1 EPS by 6c

NuVasive, Inc. (NASDAQ: NUVA) reported Q1 EPS of $0.29, $0.06 better than the analyst estimate of $0.23. Revenue for the quarter came in at $177.5 million versus the consensus estimate of $171.3 million.

Alex Lukianov, Chairman and Chief Executive Officer, said, "Results in the first quarter of 2014 were solidly in line with our expectations, and place us on track to achieve full year guidance by continuing to execute our share-taking strategy. While staying true to NuVasive's core philosophy of driving innovation to improve spine patient outcomes, we are evolving our organization to maintain a start-up mentality and to continue to lead spine innovation as a much larger, and increasingly profitable, global organization."

For earnings history and earnings-related data on NuVasive, Inc. (NUVA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'